Philip Morris (PM) Offering Possible 9.41% Return Over the Next 7 Calendar Days

Philip Morris's most recent trend suggests a bullish bias. One trading opportunity on Philip Morris is a Bull Put Spread using a strike $74.00 short put and a strike $69.00 long put offers a potential 9.41% return on risk over the next 7 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $74.00 by expiration. The full premium credit of $0.43 would be kept by the premium seller. The risk of $4.57 would be incurred if the stock dropped below the $69.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Philip Morris is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Philip Morris is bullish.

The RSI indicator is at 62.5 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Philip Morris

Philip Morris Stock Rises 3%
Thu, 02 Apr 2020 12:14:00 +0000
Investing.com – Philip Morris (NYSE:PM) Stock rose by 3.11% to trade at $73.54 by 12:12 (16:12 GMT) on Thursday on the NYSE exchange.

Coronavirus Vaccine Race Gets Unlikely Partner: Big Tobacco
Wed, 01 Apr 2020 11:05:17 +0000
(Bloomberg) — Cigarette makers may seem like an unlikely source of life-saving vaccines, yet Philip Morris International Inc. and British American Tobacco Plc are trying to devise a defense against the coronavirus from the humble tobacco leaf.BAT said Wednesday that it’s in pre-clinical testing of a plant-based vaccine via a U.S. biotech subsidiary Kentucky BioProcessing. Philip Morris has said its partially owned Canadian unit Medicago expects to start human trials for a potential vaccine this summer.“We believe we have made a significant breakthrough,” said David O’Reilly, BAT’s director of scientific research. “We stand ready to work with governments and all stakeholders to help win the war against Covid-19.”Big Tobacco isn’t a total stranger to the field: BAT’s Kentucky BioProcessing was involved in developing ZMapp, an Ebola drug, with Mapp Biopharmaceutical Inc. in 2014 — but that treatment never made it out of the lab. The race to find a vaccine is essential as world leaders question how long countries can remain in lockdown without extinguishing future economic prospects.The involvement of tobacco companies in the fight against Covid-19 may strike some as paradoxical as the World Health Organization has said smoking may raise the risk of coming down with more severe reactions to the disease.Philip Morris’s Medicago uses a virus-like particle grown in a close relative of the tobacco plant. Plant-based vaccines mimic viruses and allow the body’s immune system to recognize them and create an immune response, without being able to infect or replicate.Kentucky BioProcessing recently cloned a portion of Covid-19’s genetic sequence, which led to a substance that induces the production of antibodies. The antigen was then inserted into tobacco plants for reproduction. According to BAT, the method generates the vaccine faster than conventional methods, reducing the time required from several months to about six weeks.BAT’s U.S. unit Reynolds American bought Kentucky BioProcessing in 2014 planning to use its tobacco extraction technology to develop alternatives to cigarettes. The company is now exploring partnerships with government agencies to bring the experimental vaccine to clinical studies. BAT said while the unit is a commercial business, its work on a Covid-19 vaccine will be on a not-for-profit basis.Researchers in China were quick to share the virus’s genetic sequence with other scientists, providing them with a headstart to hunt for treatments and vaccines. They are testing everything from drugs first developed for HIV and the flu to antibody-containing plasma from recovered patients.(Updates with smoking’s effect on Covid-19 patients in fifth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla
Tue, 31 Mar 2020 16:43:04 +0000
The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla

Looks Like the Wrong Time to Quit Smoking
Tue, 31 Mar 2020 12:09:32 +0000
(Bloomberg Opinion) — Lloyd Bridges’s character in the disaster comedy “Airplane” captured it quite well when he said, “Looks like I picked the wrong week to quit smoking.” It’s a sentiment shared by people locked down around the world. While demand for most everything outside of food and toilet paper has declined, cigarettes are holding up.In an environment where companies are ditching their profit guidance left, right and center, Imperial Brands Plc, which makes Kool and Gauloises cigarettes, said on Tuesday that so far the virus had had no material impact on performance and trading remained in line with expectations. That echoes comments two weeks ago from British American Tobacco Plc. Shares in Imperial rose as much as 15%In the coronavirus-induced consumer crisis, big tobacco is certainly living up to its defensive reputation.After all, if people are addicted to nicotine, they still need their fix. And the pandemic-stricken world we live in provides incentives to light up more often:  Anxiety induced by ever-grimmer headlines; the fact that local stores selling cigarettes are still open; and the ease with which you can take a fag break when working from home as opposed to having to step outside the office.But it’s not unqualified good news for the industry.Imperial, which also makes Golden Virginia tobacco,  said that its factories were building contingency stocks, and its Logista distribution business serving Italy, France and Spain was doing the same to ensure supplies could get through to retailers. It’s also possible that as with rice and pasta, consumers are stockpiling cigarettes in case of even more stringent isolation measures down the road. So some demand may have been pulled forward, meaning this uptick might not be sustained in the long term.What’s more concerning is a recent focus on the increased risk of Covid-19 to smokers, and whether that may encourage more people to quit once the crisis has passed. Reports that the state of New York was in discussions about potentially banning cigarettes made headlines, but Bloomberg News reported on Monday that consideration of a ban was “100% not true.”Still, a renewed focus on personal health, especially where everyone’s lungs are concerned, would likely hurt cigarette sales in the future. These are all challenges tobacco companies will have to grapple with as they race to find what alternative product will drive growth if or when the world does kick its cigarette habit. The industry was already working to get past questions about health risks around vaping, which was last year linked with a spate of cases of respiratory illness. Groups including BAT, Altria Group Inc. and Philip Morris International Inc. have invested billions of dollars in electronic cigarettes and devices that heat rather than burn tobacco. Altria took a 35% stake in vaping leader Juul Labs Inc., which it has now written down. Right now, though, with the prospect of economic conditions deteriorating, tobacco’s resilience in the face of recession should come to the fore, especially given that traditional cigarettes remain the industry’s most profitable product. Smokers may trade down if money becomes tight, or switch to rolling their own cigarettes. But Duncan Fox, an analyst at Bloomberg Intelligence, says that even then pure tobacco has higher margins.So from a position a few months ago, where vaping sales were under pressure, but there were worries about an accelerated decline in smoking traditional cigarettes too, Big Tobacco’s core business now looks to be on a surer footing. That’s bad for public health, and for those funds that choose not to invest in cigarettes. But at least it can help preserve the industry’s profits and chunky dividend payouts for investors, when those at many other companies are suffering.This column does not necessarily reflect the opinion of Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

Top Analyst Reports for Alphabet, Procter & Gamble & Philip Morris
Mon, 30 Mar 2020 18:25:06 +0000
Top Analyst Reports for Alphabet, Procter & Gamble & Philip Morris

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.